Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9539-9
Annals of Surgical Oncology 14:3202-3209 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iyer, R. V.
Right arrow Articles by Javle, M. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Iyer, R. V.
Right arrow Articles by Javle, M. M.

Original Article

A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study

Renuka V. Iyer, MD1,5, John Gibbs, MD2, Boris Kuvshinoff, MD2, Marwan Fakih, MD1, James Kepner, PhD3, Nancy Soehnlein1, David Lawrence4 and Milind M. Javle, MD1

1 Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
2 Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
3 American Cancer Society, Atlanta, GA, USA
4 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA
5 Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Correspondence: Address correspondence and reprint requests to: Renuka V. Iyer, MD; E-mail: Renuka.Iyer{at}roswellpark.org

Aim: To determine the clinical benefit response (CBR), time to tumor progression (TTP), overall survival, and effect on quality of life (QOL) of gemcitabine and capecitabine in patients with advanced biliary cancer.

Methods: Gemcitabine (1000 mg/m2 IV over 30 minutes on days 1 and 8) and capecitabine (650 mg/m2 orally twice daily for 14 days) were administered and repeated every 21 days. All patients completed the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Pancreatic Cancer Module (EORTC QLQ-C30-PAN 26) questionnaire on day 1 of each cycle. Cumulative QOL scores were calculated. The two-stage design required 17 patients to evaluate the confirmed response at nine weeks.

Results: Twelve patients with a median age of 54 years were enrolled. A median of eight cycles per patient were completed. With a median follow-up of 18.2 months, the CBR (two partial response and five stable disease) was 58% [95% confidence interval (CI) 28–85%]. Four out of seven patients with CBR had no decline in QOL with chemotherapy. The probability of survival at one year was 0.58. Median TTP and overall survival were 9.0 and 14.0 months, respectively. Nine patients had grade 3 or 4 toxicities. There were no treatment-related deaths.

Conclusions: Gemcitabine and capecitabine at this dose and schedule are well tolerated and effective and may offer clinical benefit and maintain QOL in patients with advanced biliary cancer. This regimen merits further investigation in the neoadjuvant setting.

Key Words: Biliary tract cancer • Capecitabine • Gemcitabine • Quality of life (QOL) • Chemotherapy




This article has been cited by other articles:


Home page
 The OncologistHome page
A. F. Hezel and A. X. Zhu
Systemic Therapy for Biliary Tract Cancers
Oncologist, April 1, 2008; 13(4): 415 - 423.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.